Campbell & CO Investment Adviser LLC Acquires Shares of 13,588 Glaukos Corporation $GKOS

Campbell & CO Investment Adviser LLC acquired a new position in shares of Glaukos Corporation (NYSE:GKOS) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 13,588 shares of the medical instruments supplier’s stock, valued at approximately $1,108,000.

Several other institutional investors and hedge funds have also made changes to their positions in GKOS. Norges Bank purchased a new stake in Glaukos in the second quarter valued at approximately $76,314,000. Primecap Management Co. CA raised its position in Glaukos by 50.0% in the 2nd quarter. Primecap Management Co. CA now owns 1,827,998 shares of the medical instruments supplier’s stock valued at $188,814,000 after purchasing an additional 609,523 shares during the last quarter. AustralianSuper Pty Ltd purchased a new stake in Glaukos in the 2nd quarter valued at $41,946,000. William Blair Investment Management LLC boosted its stake in Glaukos by 52.4% during the 2nd quarter. William Blair Investment Management LLC now owns 1,136,095 shares of the medical instruments supplier’s stock worth $117,347,000 after purchasing an additional 390,805 shares during the period. Finally, Champlain Investment Partners LLC purchased a new position in Glaukos during the 2nd quarter worth $37,497,000. 99.04% of the stock is owned by hedge funds and other institutional investors.

Glaukos Price Performance

Glaukos stock opened at $120.59 on Monday. The company has a market cap of $6.93 billion, a P/E ratio of -78.31 and a beta of 0.67. Glaukos Corporation has a one year low of $73.16 and a one year high of $163.71. The business has a fifty day moving average of $107.30 and a two-hundred day moving average of $95.48. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.47 and a current ratio of 5.20.

Glaukos (NYSE:GKOS) last announced its quarterly earnings results on Wednesday, October 29th. The medical instruments supplier reported ($0.16) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.11. Glaukos had a negative net margin of 18.65% and a negative return on equity of 7.52%. The business had revenue of $133.54 million during the quarter, compared to the consensus estimate of $122.55 million. During the same quarter last year, the firm posted ($0.28) EPS. The business’s revenue was up 38.1% compared to the same quarter last year. As a group, analysts predict that Glaukos Corporation will post -1.08 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the stock. UBS Group upped their target price on shares of Glaukos from $140.00 to $145.00 and gave the company a “buy” rating in a report on Tuesday, December 23rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Glaukos in a research note on Wednesday, October 8th. The Goldman Sachs Group reiterated a “buy” rating and issued a $138.00 target price on shares of Glaukos in a research note on Friday, January 9th. Needham & Company LLC reissued a “buy” rating and issued a $125.00 target price on shares of Glaukos in a report on Wednesday, January 14th. Finally, Wells Fargo & Company increased their price target on Glaukos from $120.00 to $122.00 and gave the stock an “overweight” rating in a report on Thursday, October 30th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $127.92.

Insider Transactions at Glaukos

In related news, COO Joseph E. Gilliam sold 19,340 shares of the company’s stock in a transaction that occurred on Tuesday, November 18th. The stock was sold at an average price of $90.00, for a total value of $1,740,600.00. Following the sale, the chief operating officer owned 92,366 shares in the company, valued at $8,312,940. This represents a 17.31% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Alex R. Thurman sold 315 shares of the business’s stock in a transaction on Tuesday, November 25th. The stock was sold at an average price of $105.00, for a total value of $33,075.00. Following the sale, the chief financial officer owned 50,488 shares in the company, valued at approximately $5,301,240. The trade was a 0.62% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 24,655 shares of company stock valued at $2,310,025 in the last quarter. 5.80% of the stock is currently owned by corporate insiders.

Glaukos Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.